DexCom Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

DexCom hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

4.2%

Rückkaufsrendite

Gesamte Aktionärsrendite	4.2%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von DXCM in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von DXCM gestiegen sind.

Dividendenrendite im Vergleich zum Markt

DexCom Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von DXCM im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (DXCM)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Medical Equipment)	1.7%
Analystenprognose (DXCM) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von DXCM im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von DXCM im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von DXCM, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da DXCM keine Ausschüttungen gemeldet hat.

DexCom Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $750 million worth of its shares.

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Recent updates

Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

Third quarter 2024 earnings: EPS misses analyst expectations

DexCom Growing Into Its Valuation, But Still No Bargain

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

Kessler Topaz Meltzer & Check, LLP Files Class Action Lawsuit Against Dexcom, Inc

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom: Investors Discounting Long CGM Growth Runway

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium

Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of DexCom, Inc

DexCom Q2 Earnings: Traditional Market Overreaction

Investor sentiment deteriorates as stock falls 37%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 41% undervalued after recent price drop

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $750 million worth of its shares.

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

DexCom, Inc. to Report Q2, 2024 Results on Jul 25, 2024

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Now 22% overvalued after recent price rise

Dexcom: Positive Catalysts Ahead To Support Growth

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

DexCom, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

DexCom, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

DexCom, Inc., Annual General Meeting, May 22, 2024

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Now 24% overvalued after recent price rise

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Executive Chairman recently sold US$4.0m worth of stock

Executive Chairman notifies of intention to sell stock

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Executive VP notifies of intention to sell stock

DexCom: A Wealth Compounder In Healthcare

Full year 2023 earnings: EPS exceeds analyst expectations

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Executive Chairman recently sold US$4.6m worth of stock

DexCom: Stelo Stellar Outlook

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Insufficient new directors

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt